Interestingly, CIP2A-mediated PP2A inhibition or pharmacological inhibition of PP2A using okadaic acid (OA) increases c-MYC levels and contributes to sensitivity to chemotherapies such as paclitaxel, doxorubicin and temozolomide in melanoma cells [9,110]. The gene discussed is MYC; the disease is melanoma.